Alpha 2.0
Login Register
» Authors » Wei-Tao Zhuang

Wei-Tao Zhuang

Explore the profile of Wei-Tao Zhuang including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 17
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
Pharmacology
Top 10 Co-Authors
Wen-Feng Fang
Jun Liao
Lan-Lan Pang
Li Zhang
Yi-Hua Huang
Ya-Xiong Zhang
Yi Lv
Meng-Di Li
Li-Yang Hu
Jia-Di Gan
Published In
J Thorac Oncol
Int J Cancer
J Natl Compr Canc Netw
BMC Cancer
Signal Transduct Target Ther
Affiliations
Soon will be listed here.
Recent Articles
1.
Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis
Pang L, Zhuang W, Chen Z, Liao J, Li M, Zhang L, et al.
J Natl Compr Canc Netw . 2025 Mar; :1-8. PMID: 40081325
Background: Traditional chemotherapy provides restricted benefits for advanced EGFR-mutant non-small cell lung cancer (NSCLC) after failure of EGFR-tyrosine kinase inhibitors (EGFR-TKIs), necessitating the combined treatment. However, it remains controversial which...
2.
Specifying the choice of EGFR-TKI based on brain metastatic status for advanced NSCLC with EGFR p.L861Q mutation
Pang L, Zhuang W, Li J, Li B, Huang Y, Liao J, et al.
Neoplasia . 2024 Oct; 58:101073. PMID: 39427513
Background: In-depth insight into the genomic features of the uncommon EGFR p.L861Q mutant NSCLC is scarcely performed, and no consensus on the preferred treatment strategy has been established. Moreover, the...
3.
Response to Commentary on "EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47"
Zhuang W, Hu L, Fang W
J Thorac Oncol . 2024 Oct; 19(10):e50-e51. PMID: 39370222
No abstract available.
4.
Mex-3 RNA binding family member A (MEX3A)/circMPP6 complex promotes colorectal cancer progression by inhibiting autophagy
Chen R, Xu S, Deng M, Hao S, Chen J, Ma X, et al.
Signal Transduct Target Ther . 2024 Apr; 9(1):80. PMID: 38565536
RNA-binding proteins (RBPs)-RNA networks have contributed to cancer development. Circular RNAs (circRNAs) are considered as protein recruiters; nevertheless, the patterns of circRNA-protein interactions in colorectal cancer (CRC) are still lacking....
5.
EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47
Hu L, Zhuang W, Chen M, Liao J, Wu D, Zhang Y, et al.
J Thorac Oncol . 2024 Mar; 19(8):1186-1200. PMID: 38553005
Introduction: EGFR-mutated NSCLC is characterized by an immunosuppressive microenvironment that confers limited clinical effectiveness to anti-PD-1 or PD-L1 antibodies. Despite the discouraging outcomes of immunotherapy, novel immune checkpoints are constantly...
6.
Uncommon de novo EGFR-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment
Pang L, Zhuang W, Huang Y, Liao J, Li M, Lv Y, et al.
Lung Cancer . 2024 Mar; 190:107528. PMID: 38461768
Introduction: The literature on de novo EGFR-mutant patients diagnosed with lung cancer is limited, and there is currently no consensus concerning the most effective treatment protocols. This study aimed to...
7.
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Pang L, Gan J, Huang Y, Liao J, Zhuang W, Ali W, et al.
BMC Cancer . 2023 Jan; 23(1):72. PMID: 36670414
Background & Objective: "Anti-angiogenetic drugs plus chemotherapy" (anti-angio-chemo) and "immune checkpoint inhibitors plus chemotherapy" (ICI-chemo) are superior to traditional chemotherapy in the first-line treatment of patients with advanced non-small-cell lung...
8.
Exploration of immunotherapy in advanced pulmonary lymphoepithelioma-like carcinoma
Pang L, Liao J, Huang Y, Gan J, Zhuang W, Lv Y, et al.
Int J Cancer . 2023 Jan; 152(11):2338-2350. PMID: 36631999
Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare and histologically distinctive subtype of nonsmall cell lung cancer (NSCLC). High expression of programmed death ligand 1 (PD-L1) and scarcity of druggable driver...